Dermatology in 2025: Year in Review

In 2025, HCPLive has spotlighted many major developments in dermatology in our coverage, spanning high-impact clinical trial readouts, regulatory decisions by the US Food and Drug Administration (FDA), and evolving standards of care for chronic skin conditions. Notable news headlines included updated safety and efficacy findings on oral small molecules such as Janus Kinase (JAK) inhibitors, continued expansion of biologic and targeted drugs into new dermatologic indications, and growing attention to the role of artificial intelligence (AI) and digital tools in the field.